Synthaverse S.A. (SVE.WA)
PLN 4.28
(7.0%)
PLN 4.28
(7.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 26.35 Million PLN | 41.1% |
| 2022 | 18.67 Million PLN | 15.93% |
| 2021 | 16.11 Million PLN | 14.25% |
| 2020 | 14.1 Million PLN | -8.75% |
| 2019 | 15.45 Million PLN | -3.75% |
| 2018 | 16.05 Million PLN | -4.79% |
| 2017 | 16.86 Million PLN | -14.37% |
| 2016 | 19.69 Million PLN | 18.83% |
| 2015 | 16.57 Million PLN | 32.35% |
| 2014 | 12.52 Million PLN | -41.37% |
| 2013 | 21.35 Million PLN | -23.97% |
| 2012 | 28.09 Million PLN | 8.82% |
| 2011 | 25.81 Million PLN | 0.44% |
| 2010 | 25.7 Million PLN | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 6.38 Million PLN | -6.96% |
| 2024 Q2 | 6.57 Million PLN | 4.49% |
| 2023 Q4 | 6.86 Million PLN | -14.77% |
| 2023 Q3 | 8.05 Million PLN | 13.66% |
| 2023 Q2 | 7.08 Million PLN | 49.89% |
| 2023 FY | 26.35 Million PLN | 41.1% |
| 2023 Q1 | 4.72 Million PLN | 2.94% |
| 2022 Q4 | 4.59 Million PLN | -13.36% |
| 2022 Q3 | 5.29 Million PLN | 8.3% |
| 2022 Q2 | 4.89 Million PLN | 25.62% |
| 2022 Q1 | 3.89 Million PLN | -17.81% |
| 2022 FY | 18.67 Million PLN | 15.93% |
| 2021 Q1 | 4.02 Million PLN | 14.79% |
| 2021 Q2 | 3.87 Million PLN | -3.82% |
| 2021 Q3 | 3.46 Million PLN | -10.53% |
| 2021 FY | 16.11 Million PLN | 14.25% |
| 2021 Q4 | 4.73 Million PLN | 36.69% |
| 2020 Q4 | 3.51 Million PLN | 22.86% |
| 2020 FY | 14.1 Million PLN | -8.75% |
| 2020 Q1 | 3.54 Million PLN | -14.78% |
| 2020 Q2 | 4.18 Million PLN | 18.08% |
| 2020 Q3 | 2.85 Million PLN | -31.76% |
| 2019 FY | 15.45 Million PLN | -3.75% |
| 2019 Q1 | 4.33 Million PLN | -4.72% |
| 2019 Q2 | 3.88 Million PLN | -10.4% |
| 2019 Q3 | 3.06 Million PLN | -21.12% |
| 2019 Q4 | 4.16 Million PLN | 35.71% |
| 2018 Q4 | 4.55 Million PLN | 14.17% |
| 2018 Q3 | 3.98 Million PLN | -5.36% |
| 2018 Q2 | 4.21 Million PLN | 27.7% |
| 2018 Q1 | 3.3 Million PLN | 145.68% |
| 2018 FY | 16.05 Million PLN | -4.79% |
| 2017 Q3 | 3.94 Million PLN | -74.35% |
| 2017 FY | 16.86 Million PLN | -14.37% |
| 2017 Q4 | -7.22 Million PLN | -283.21% |
| 2017 Q2 | 15.37 Million PLN | 314.0% |
| 2017 Q1 | 3.71 Million PLN | 1.45% |
| 2016 Q3 | 4.94 Million PLN | -31.43% |
| 2016 Q4 | 3.66 Million PLN | -25.96% |
| 2016 FY | 19.69 Million PLN | 18.83% |
| 2016 Q1 | 3.88 Million PLN | -36.78% |
| 2016 Q2 | 7.2 Million PLN | 85.75% |
| 2015 Q2 | 4.08 Million PLN | 37.87% |
| 2015 Q3 | 3.38 Million PLN | -17.11% |
| 2015 FY | 16.57 Million PLN | 32.35% |
| 2015 Q4 | 6.13 Million PLN | 81.3% |
| 2015 Q1 | 2.96 Million PLN | 165.17% |
| 2014 Q3 | 6.07 Million PLN | 6.61% |
| 2014 FY | 12.52 Million PLN | -41.37% |
| 2014 Q1 | 5.29 Million PLN | -6.81% |
| 2014 Q2 | 5.69 Million PLN | 7.48% |
| 2014 Q4 | -4.54 Million PLN | -174.87% |
| 2013 Q4 | 5.68 Million PLN | 20.98% |
| 2013 Q2 | 5.43 Million PLN | -1.83% |
| 2013 Q3 | 4.7 Million PLN | -13.51% |
| 2013 Q1 | 5.53 Million PLN | -16.6% |
| 2013 FY | 21.35 Million PLN | -23.97% |
| 2012 Q4 | 6.63 Million PLN | 12.87% |
| 2012 FY | 28.09 Million PLN | 8.82% |
| 2012 Q2 | 6.45 Million PLN | -29.17% |
| 2012 Q3 | 5.88 Million PLN | -8.91% |
| 2012 Q1 | 9.11 Million PLN | 0.0% |
| 2011 FY | 25.81 Million PLN | 0.44% |
| 2010 FY | 25.7 Million PLN | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bioceltix S.A. | 15.38 Million PLN | -71.299% |
| BIOTON S.A. | 57.55 Million PLN | 54.213% |
| Captor Therapeutics Spolka Akcyjna | 79.91 Million PLN | 67.023% |
| Mabion S.A. | 59.52 Million PLN | 55.724% |
| Molecure S.A. | 31.73 Million PLN | 16.944% |
| NanoGroup S.A. | 7.82 Million PLN | -236.721% |
| Pharmena S.A. | -32.76 Million PLN | 180.433% |
| Poltreg S.A. | 15.47 Million PLN | -70.3% |
| Pure Biologics Spólka Akcyjna | 29.14 Million PLN | 9.573% |
| Ryvu Therapeutics S.A. | 4.73 Million PLN | -456.226% |
| Urteste S.A. | 5.96 Million PLN | -341.588% |